Fatemeh Malekzadeh|Tom Marshall|Akram Pourshams|M. Gharravi|Afshin Aslani|Alireza Nateghi|Mansoor Rastegarpanah|Masoud Khoshnia|Shahryar Semnani|Rasool Salahi|G. Neil Thomas|Bagher Larijani|Kar Keung Cheng|Reza Malekzadeh
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors
Shariati Hospital|Tehran University of Medical Sciences|University of Birmingham|Shariati Hospital|Tehran University of Medical Sciences|Shariati Hospital|Tehran University of Medical Sciences|Shariati Hospital|Tehran University of Medical Sciences|Shariati Hospital|Tehran University of Medical Sciences|Tehran University of Medical Sciences|Shariati Hospital|Tehran University of Medical Sciences|Golestan University|Golestan University of Medical Sciences|Golestan University|Golestan University of Medical Sciences|University of Birmingham|Shariati Hospital|Tehran University of Medical Sciences|University of Birmingham|Shariati Hospital|Tehran University of Medical Sciences
objective investigate effects tolerability fixeddose combination therapy blood pressure ldl adults without elevated blood pressure lipid levelsthis doubleblind randomised placebocontrolled trial residents kalaleh golestan iran following 8week placebo runin period 475 participants aged 50 79 years without cardiovascular disease hypertension hyperlipidaemia randomised fixeddose combination therapy aspirin 81 mg enalapril 25 mg atorvastatin 20 mg hydrochlorothiazide 125 mg polypill placebo period 12 months primary outcomes changes ldlcholesterol systolic diastolic blood pressure adverse reactions analysis intentiontotreat basisat baseline differences systolic blood pressure 6 mmhg taking account baseline differences 12 months polypill associated statistically significant reductions blood pressure 4516 mmhg ldlcholesterol 046 mmoll study drug well tolerated resulted modest reductions blood pressure lipid levelsthe effects polypill blood pressure lipid levels less anticipated raising questions reliability reported compliance case fully powered trial polypill prevention cardiovascular disease